The stock of ZyVersa Therapeutics Inc (NASDAQ: ZVSA) has increased by 7.85 when compared to last closing price of 0.64.Despite this, the company has seen a gain of 5.86% in its stock price over the last five trading days. globenewswire.com reported 2025-05-20 that Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in promoting accumulation and spread of toxic phosphorylated alpha-synuclein leading to neurodegeneration in Parkinson’s Disease (PD). Our data showed that microglial inflammation was driven by activation of NLRP1 inflammasomes triggered by ASC specks and alpha-synuclein aggregates.
Is It Worth Investing in ZyVersa Therapeutics Inc (NASDAQ: ZVSA) Right Now?
Additionally, the 36-month beta value for ZVSA is 0.75. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ZVSA is 4.76M and currently, short sellers hold a 4.66% ratio of that float. The average trading volume of ZVSA on June 10, 2025 was 3.59M shares.
ZVSA’s Market Performance
ZVSA stock saw an increase of 5.86% in the past week, with a monthly gain of 30.88% and a quarterly increase of -27.43%. The volatility ratio for the week is 3.91%, and the volatility levels for the last 30 days are 4.53% for ZyVersa Therapeutics Inc (ZVSA). The simple moving average for the past 20 days is 17.45% for ZVSA’s stock, with a -48.70% simple moving average for the past 200 days.
ZVSA Trading at 6.50% from the 50-Day Moving Average
After a stumble in the market that brought ZVSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.05% of loss for the given period.
#####
#####
Stock Fundamentals for ZVSA
The total capital return value is set at -0.24. Equity return is now at value -91.39, with -41.48 for asset returns.
Currently, EBITDA for the company is -9.14 billion with net debt to EBITDA at 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.18.
Conclusion
In conclusion, ZyVersa Therapeutics Inc (ZVSA) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
